Insufficient Evidence to Consider CCL21 a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al
- PMID: 30653848
- DOI: 10.1002/art.40819
Insufficient Evidence to Consider CCL21 a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al
Comment in
-
Reply.Arthritis Rheumatol. 2019 Apr;71(4):655-656. doi: 10.1002/art.40816. Epub 2019 Mar 2. Arthritis Rheumatol. 2019. PMID: 30663863 No abstract available.
Comment on
-
CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis.Arthritis Rheumatol. 2018 Oct;70(10):1644-1653. doi: 10.1002/art.40534. Epub 2018 Aug 30. Arthritis Rheumatol. 2018. PMID: 29687634
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
